HNF-3M-NM-1 / FOXA1 antibody (mAb) | Active Motif 39837 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Active Motif

other brands :

Geneka Biotechnology

product type :

antibody

product name :

HNF-3M-NM-1 / FOXA1 antibody (mAb)

catalog :

39837

quantity :

100 ug

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

2F83

The same clone is also sold as:

BioLegend: 612001, 612003, 612002, 612004

reactivity :

human, mouse

application :

western blot, immunohistochemistry

citations: 1

Reference
An J, Jang S, Kim J, Kim C, Song P, Choi K. The expression of p21 is upregulated by forkhead box A1/2 in p53-null H1299 cells. FEBS Lett. 2014;588:4065-70 pubmed publisher

product information

Catalog Number :

39837

Product Name :

HNF-3M-NM-1 / FOXA1 antibody (mAb)

Host Species :

Mouse

Clonality :

Monoclonal

Size :

100 ug

Clone :

2F83

Isotype :

IgG

CrossReactivity :

Human, Mouse

Background :

HNF-3M-NM-1 (Hepatocyte nuclear factor 3 alpha, forkhead box A1, FoxA1) is a homeodomain containing transcription factor and is a member of the Hepatocyte Nuclear Factor family (HNF-1M-NM-1, HNF-1M-NM-2, HNF-3M-NM-1, HNF-3M-NM-2, HNF-3M-NM-3, HNF-4M-NM-1, HNF-4M-NM-3, HNF-6M-NM-1 and HNF-6M-NM-2), whose members regulate the transcription of numerous hepatocyte genes in adult liver. HNF-3 members bind to DNA as monomers using a winged helix DNA-binding domain. HNF-3M-NM-1 and HNF-3M-NM-3 have also been shown to be involved in gastrulation events such as body axis formation.

Immunogen :

This HNF-3M-NM-1 / FOXA1 antibody was raised against a recombinant protein corresponding to amino acids 7-103 of rat HNF-3M-NM-1 /FOXA1.

Uses :

IHC, WB

Storage :

Antibodies in solution can be stored at -20M-BM-0C for 2 years. Avoid repeated freeze/thaw cycles and keep on ice when not in storage.

Product References :

References: This antibody has been used as described in the following references: IHC: Albergaria A et al. (2009) Breast Cancer Res 11: R40 IHC: Nucera C et al. (2009) Clin Cancer Res 15: 3680-3689